$NBIO news alert: Apr 12, 2022 (ACCESSWIRE via COM
Post# of 53479
(Total Views: 163)
Posted On: 04/12/2022 8:18:01 AM
$NBIO news alert: Apr 12, 2022 (ACCESSWIRE via COMTEX) -- VERO BEACH, FL / ACCESSWIRE / April 12, 2022 / Nascent Biotech, developer of Pritumumab (PTB), a monoclonal antibody showing promise in the treatment of brain cancer, has partnered with BioTools, Inc to clearly define PTB's higher order molecular structure (HOS).
Nascent is exploring the potential of modifying the antibody to enhance its effectiveness and to broaden its therapeutic application. BioTool's groundbreaking ROA laser-based technology provides detailed and complete structural characterization at all stages of development including formulation and stability. ROA spectrum generates a structural snapshot and unique signature for each product and each modification.
PTB is a natural human IgG1 antibody isolated from a patient with cervical carcinoma. It is a protein molecule comprised of multiple amino acid units linked together into a chain which can then fold into various configurations. Both the folding ("secondary structure"
and the more extensive, 3-dimensional results ("tertiary structure" have dramatic impact on the molecule's pharmaceutical effectiveness.
"BioTools is known worldwide for their knowledge and expertise in the field of Raman, ROA, and biologic FTIR. We are very pleased to have had an opportunity to work with their scientists to deliver this refined capability for our monoclonal antibody (mAb) development platform."-Sean Carrick, CEO, Nascent Biotech Inc.
"Nascent's mAb PTB is an ideal match for our instrumentation as well as for our vision of expanding Raman/ROA+FTIR to more widespread, routine use in BioPharma research labs. This suite of techniques, coupled with the accompanying BioTools' databases and software, have powerful application to the characterization of higher order structures for many therapeutics."-BioTools, President & Co-Founder, Dr. Rina Dukor
Nascent is exploring the potential of modifying the antibody to enhance its effectiveness and to broaden its therapeutic application. BioTool's groundbreaking ROA laser-based technology provides detailed and complete structural characterization at all stages of development including formulation and stability. ROA spectrum generates a structural snapshot and unique signature for each product and each modification.
PTB is a natural human IgG1 antibody isolated from a patient with cervical carcinoma. It is a protein molecule comprised of multiple amino acid units linked together into a chain which can then fold into various configurations. Both the folding ("secondary structure"
and the more extensive, 3-dimensional results ("tertiary structure" have dramatic impact on the molecule's pharmaceutical effectiveness. "BioTools is known worldwide for their knowledge and expertise in the field of Raman, ROA, and biologic FTIR. We are very pleased to have had an opportunity to work with their scientists to deliver this refined capability for our monoclonal antibody (mAb) development platform."-Sean Carrick, CEO, Nascent Biotech Inc.
"Nascent's mAb PTB is an ideal match for our instrumentation as well as for our vision of expanding Raman/ROA+FTIR to more widespread, routine use in BioPharma research labs. This suite of techniques, coupled with the accompanying BioTools' databases and software, have powerful application to the characterization of higher order structures for many therapeutics."-BioTools, President & Co-Founder, Dr. Rina Dukor
(0)
(0)Scroll down for more posts ▼